Evaluating the activity of N-89 as an oral antimalarial drug
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Despite the recent progress in public health measures, malaria remains a troublesome disease that needs to be eradicated. It is essential to develop new antimalarial medications that are reliable and secure. This report evaluated the pharmacokinetics and antimalarial activity of 1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) using the rodent malaria parasite Plasmodium berghei in vivo. After a single oral dose (75 mg /kg) of N-89, its pharmacokinetic parameters were measured, and t1/2 was 0.97 h, Tmax was 0.75 h, and bioavailability was 7.01%. A plasma concentration of 8.1 ng/ml of N-89 was maintained for 8 h but could not be detected at 10 h. The dose inhibiting 50% of parasite growth (ED50) and ED90 values of oral N-89 obtained following a 4-day suppressive test were 20 and 40 mg/kg, respectively. Based on the plasma concentration of N-89, we evaluated the antimalarial activity and cure effects of oral N-89 at a dose of 75 mg/kg 3 times daily for 3 consecutive days in mice harboring more than 0.5% parasitemia. In all the N-89- treated groups, the parasites were eliminated on day 5 post-treatment, and all mice recovered without a parasite recurrence for 30 days. Additionally, administering oral N-89 at a low dose of 50 mg/kg was sufficient to cure mice from day 6 without parasite recurrence. This work was the first to investigate the pharmacokinetic char-acteristics and antimalarial activity of N-89 as an oral drug. In the future, the following steps should be focused on developing N-89 for malaria treatments; its administration schedule and metabolic pathways should be investigated.
Abstract
Despite the recent progress in public health measures, malaria remains a troublesome disease that needs to be eradicated. It is essential to develop new antimalarial medications that are reliable and secure. This report evaluated the pharmacokinetics and antimalarial activity of 1,2,6,7-tetraoxaspiro[7.11]nonadecane (N-89) using the rodent malaria parasite Plasmodium berghei in vivo. After a single oral dose (75 mg /kg) of N-89, its pharmacokinetic parameters were measured, and t1/2 was 0.97 h, Tmax was 0.75 h, and bioavailability was 7.01%. A plasma concentration of 8.1 ng/ml of N-89 was maintained for 8 h but could not be detected at 10 h. The dose inhibiting 50% of parasite growth (ED50) and ED90 values of oral N-89 obtained following a 4-day suppressive test were 20 and 40 mg/kg, respectively. Based on the plasma concentration of N-89, we evaluated the antimalarial activity and cure effects of oral N-89 at a dose of 75 mg/kg 3 times daily for 3 consecutive days in mice harboring more than 0.5% parasitemia. In all the N-89- treated groups, the parasites were eliminated on day 5 post-treatment, and all mice recovered without a parasite recurrence for 30 days. Additionally, administering oral N-89 at a low dose of 50 mg/kg was sufficient to cure mice from day 6 without parasite recurrence. This work was the first to investigate the pharmacokinetic char-acteristics and antimalarial activity of N-89 as an oral drug. In the future, the following steps should be focused on developing N-89 for malaria treatments; its administration schedule and metabolic pathways should be investigated.
참고문헌 (28)
- "World Malaria Report 2022" (2022)[URL]
- "Guidelines for the Treatment of Malaria" (2022)[URL]
- van der Pluijm RW, "Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam : a prospective clinical, pharmacological, and genetic study", Lancet Infect Dis, 19(9), pp.952~961 (2019)[DOI]
- Imwong M, "The spread of artemisinin-resistant Plasmodium falciparum in the Greater Mekong subregion : a molecular epidemiology observational study", Lancet Infect Dis, 17(5), pp.491~497 (2017)[DOI]
- Dormoi J, "Methylene blue-based combination therapy with amodiaquine prevents severe malaria in an experimental rodent model", Pharma-ceutics, 14(10), pp.2031~ (2022)[DOI]
- Khairani S, "Oral administration of piperine as curative and prophylaxis reduces parasitaemia in Plasmodium berghei ANKAinfected mice", J Trop Med, 2022, pp.5721449~ (2022)[DOI]
- Gebremariam GK, "In Vivo antimalarial activity of leaf latex of Aloe melanacantha against Plasmodium berghei infected mice", J Trop Med, 2021, pp.6690725~ (2021)[DOI]
- Kim HS, "Synthesis and antimalarial activity of novel medium-sized 1, 2, 4, 5-tetraoxacycloalkanes", J Med Chem, 44, pp.2357~2361 (2001)[DOI]
- Aly NS, "Proteome analysis of new antimalarial endoperoxide against Plasmodium falciparum", Parasitol Res, 100(5), pp.1119~1124 (2007)[DOI]
- Morita M, "Stage specific activity of synthetic antimalarial endoperoxides, N-89and N-251, against Plasmodium falciparum", Parasitol Int, 64(1), pp.113~117 (2015)[DOI]
- nonadec-4-yl)hexan-1-ol, "Parasitol Int", 2011, 270~273, https:
- Aly NSM, "Formulation and evaluation of the antimalarial N-89 as a transdermal drug candidate", Parasitol Int, 93, pp.102720~ (2023)[DOI]
- Aly NSM, "Pioneer use of antimalarial transdermal combination therapy in rodent malaria model", Pathogens, 12(3), pp.398~ (2023)[DOI]
- Nagwa S. M. Aly, "Antimalarial effect of synthetic endoperoxide on synchronized Plasmodium chabaudi infected mice", Parasites, Hosts and Diseases, 61(1), pp.33~41 (2023), 대한기생충학ㆍ열대의학회[DOI]
- Imada C, "Improvement of oral bioavailability of N-251, a novel antimalarial drug, by increasing lymphatic transport with longchain fatty acid-based self-nanoemulsifying drug delivery system", Pharm Res, 32(8), pp.2595~2608 (2015)[DOI]
- Okada K, "Pharmacokinetic analysis of new synthetic antimalarial N-251", Trop Med Health, 47, pp.40~ (2019)[DOI]
- nonadec-4-yl)hexan-1-ol(N-251)and its carboxylic acid de-rivatives, "Parasitol Int", 2011, 488~492, https:
- Morita M, "Plasmodium falciparum endoplasmic reticulum-resident calcium binding protein is a possible target of synthetic antima-larial endoperoxides, N 89 and N 251", J Proteome Res, 11(12), pp.5704~5711 (2012)[DOI]
- La Greeca N, "Identification of an endoplasmic reticulum-resident calcium-binding protein with multiple EF-hand motifs in asexual stage of Plasmodium falciparum", Mol Biochem Parasitol, 89(2), pp.283~293 (1997)[DOI]
- Fierro MA, "An endoplasmic reticulum CREC family protein regulates the egress proteolytic cascade in malaria parasites", mBio, 11(1), pp.e03078~03019 (2020)[DOI]
- Gabriela M, "A revised mechanism for how Plasmodium falciparum recruits and exports proteins into its erythrocytic host cell", PLoS Pathog, 18(2), pp.e1009977~ (2022)[DOI]
- Tabata K, "Moment analysis pro-gram available on Microsoft Excel", Xenobio Metabol Dispos, 14, pp.286~293 (1999)[DOI]
- Hashimoto M, "Pharmacokinetic properties of orally Administered 4´-cyano-2´-deoxyguanosine, a novel nucleoside analog in-hibitor of the Hepatitis B, in viral liver injury model rats", Biol Pharm Bull, 43(9), pp.1426~1429 (2020)[DOI]
- Peters W, "The chemotherapy of rodent malaria, XXII. The value of drug-resistant strains of P. berghei in screening for blood schizontocidal activity", Ann Trop Med Parasitol, 69(2), pp.155~171 (1975)
- Alqahtani MS, "Advances in oral drug delivery", Front Pharmacol, 12, pp.618411~ (2021)[DOI]
- Fu C, "Oral bioavailability comparison of artemisinin, deoxyartemisinin, and 10-deoxoartemisinin based on computer simulations and pharmacokinetics in rats", ACS Omega, 6(1), pp.889~899 (2021)[DOI]
- Klayman DL, "Transdermal artelinic acid : an effective treatment for Plasmodium bergheiinfected mice", Am J Trop Med Hyg, 45(5), pp.602~607 (1991)[DOI]
- Lin AJ, "Antimalarial activity of dihydroartemisinin derivatives by transdermal application", Am J Trop Med Hyg, 50(6), pp.777~783 (1994)[DOI]